Co-development agreement, brokered by MaRS Innovation, to advance ultrasound chemotherapy monitoring technology as clinical tool
TORONTO (March 12, 2015) — Sunnybrook Health Sciences Centre and MaRS Innovation today announced a co-development agreement for WaveCheck, an ultrasound technology that transforms conventional equipment so that physicians can monitor a breast cancer tumour’s response to chemotherapy.
This announcement was covered in Biotechnology Focus, Aunt Minnie.com (radiology blog), dotmed.com, Bio-Medicine.org, Bloomberg Business and Research Views.
The partnership with GE Healthcare, brokered by MaRS Innovation, seeks to develop WaveCheck ...
If you work in the life sciences in Ontario, your wages are approximately 26.5 per cent higher than those of the provincial average. On the other hand, if you're a recent science graduate, you're facing a challenging unemployment rate of 18.9 per cent.
These are only two of the data points described in the Life Sciences Ontario (LSO) Sector Report 2015, which is the first of its kind to provide well-defined data that clearly measure and report on the sector's benchmarking and ...
Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, announced October 27, 2014 new and expanded strategic collaborations with Celgene Corporation.
This announcement was covered in Genetic Engineering and Biotechnology News (GEN), BioCentury Extra (no link available), Pharmaceutical Business Review (no link available), Scrip and BioWorld Today (no link available). It builds on Triphase's original collaborative agreement with Celgene in January 2014.
The company has also announced a new global license for a fully human, bi-specific ...
TORONTO (October 20, 2014) — Vasomune Therapeutics, a biotechnology start-up founded by Drs. Dan Dumont and Paul Van Slyke of Sunnybrook Research Institute (SRI) in partnership with MaRS Innovation, has received $1.5 million, in part through Genome Canada’s Genomic Applications Partnership Program (GAPP), to advance Vasculotide, the company’s lead Tie-2 activating agent, towards clinical development.
This announcement was covered in Biotechnology Focus.
The Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, announced ...
Researchers working in orphan indications, drug delivery devices, big data and other key areas invited to submit a brief Statement of Interest
The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI's industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and Merck.
The program's goal is to secure funding for researchers within MI's membership through these collaborative, strategic R&D partnership programs.
First run in November 2013, the MI-IAP allows researchers to easily ...
In a January 24, 2014 Biotechnology Focus cover article, author Shawn Lawrence discusses MaRS Innovation President and CEO Dr. Raphael (Rafi) Hofstein's recent visit to learn more of the emerging science and technology markets in Singapore and Japan.
The trip allowed Hofstein to discuss current MI projects, specifically start-ups XLV Diagnostics Inc. and DVLR Therapeutics Inc., whose products could benefit from Singapore's proximity to medical technology markets in India and China.
Hofstein joined other delegates from Canada, including Dr. Mark Poznansky, president and CEO of the ...
Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership
TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership.
Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area.
This announcement was covered by BetaKit.
His technology generates cell lines with improved protein production and survival properties, important in the ...
Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centres, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health.
Read the original release via The National Post or in French. MaRS Innovation's November 25 announcement about the partnership is also available.
This story was covered by GEN: Genetic Engineering Biotechnology News.
Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in ...
Collaboration will advance early-stage technologies and identify high-potential opportunities related to human health
TORONTO, Nov. 25, 2013 - MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, today announced a new collaboration with Johnson & Johnson Innovation and its affiliate Janssen, Inc., in Canada to advance early-stage technologies related to human health in therapeutics, medical devices, and diagnostics.
This announcement was covered by Biotechnology Focus and the Village Gamer blog.
Through the collaboration, MaRS Innovation and technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will jointly ...
Applications invited for MI’s Industry Access Program, which matches early-stage, high-potential technologies to partners and funding
MaRS Innovation (MI) has launched a unique funding program to match researchers with industry partners while advancing early stage technologies: the MaRS Innovation Industry Access Program (MI-IAP).
This program provides a simple mechanism to connect researchers with MI’s industry partners. The process and application form are intentionally brief to save researchers time and allow MI's partners to review a wide range of remarkable technologies within the Toronto academic ...